ODM-109

Drug Name: ODM-109
Company: Orion Pharma
Location: Finland
Website: https://www.orion.fi/en/rd/orion-rd/pipeline/
Drug Type: Small Molecule
Conditions: ALS
Mechanism Type: Improving muscle function
Mechanism: ODM-109 aims in part, to improve breathing in ALS by improving the performance of muscles in the diaphragm. The drug candidate, also known as oral levosimendan, increases the force of contraction of certain muscles by boosting the calcium sensitivity of troponin C.
U.S. Status for ALS: Phase III

References:
[1] Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS Clinicaltrials.gov, 17 Jul 2018. Accessed on 9 Aug 2018 from https://www.clinicaltrials.gov/ct2/show/NCT02487407.
[2] Oral levosimendan (ODM109): key placebo-controlled results from the phase 2 study in ALS patients
with SVC between 60-90% predicted at screening.
Chalabi A. et al, 2017. International Symposium on ALS/MND. Boston, Massachusetts.
[3] Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis. Clinicaltrials.gov, 28 Nov 2017. Accessed on 27 Feb 2018 from https://www.clinicaltrials.gov/ct2/show/NCT02487407.
[4] The calcium sensitizer levosimendan improves human diaphragm function. Al-Doorduin J et al., Am J Respir Crit Care Med. 2012 Jan 1;185(1):90-5.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail